PTC Therapeutics | PTCT - Operating Expenses


PTC Therapeutics reported $207.52M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Amgen USD 5.13B 1.39B Sep/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Cytokinetics USD 168.69M 9.58M Sep/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Gilead Sciences USD 4.26B 95M Sep/2025
Incyte USD 4.65B 3.75B Sep/2025
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Novartis USD 9.86B 115M Sep/2025
Pfizer USD 92.8B 82.47B Sep/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
TG Therapeutics USD 132.34M 26.04M Sep/2025
Ultragenyx Pharmaceutical USD 330.82M 56.44M Sep/2025
Vertex Pharmaceuticals USD 1.84B 27.1M Sep/2025
Xencor USD 68.52M 8.26M Sep/2025